{"product_id":"sonichealthcare-bcg-matrix","title":"Sonic Healthcare Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSonic Healthcare’s preliminary BCG Matrix highlights a mix of stable cash-generating lab services and high-growth diagnostics segments that could be Stars or Question Marks depending on regional market share—while legacy lines may be sliding toward Dogs without strategic reinvestment. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Genomic and Precision Medicine Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Sonic Healthcare’s investment in advanced genetic testing and molecular diagnostics has made it a leader in the high-growth precision medicine sector, with genomic revenue up ~42% YoY to AUD 420M in FY2025 and margins near 28%.\u003c\/p\u003e\n\u003cp\u003eThese services command high margins and rapid global adoption as clinicians shift to personalized treatment—molecular test volumes grew 35% across Australia, UK and US in 2025.\u003c\/p\u003e\n\u003cp\u003eThey need heavy R\u0026amp;D and capital equipment—Sonic reported AUD 85M in precision-medicine capex and AUD 60M R\u0026amp;D in 2025—but represent the future of its diagnostic leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Laboratory Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSonic Healthcare is scaling its U.S. pathology footprint, adding ~30 lab sites via acquisitions in 2023–2025 and lifting U.S. revenue to about US$1.1bn in FY2025, driven by both buy-and-build and organic referrals.\u003c\/p\u003e\n\u003cp\u003eThe U.S. market grows ~6–7% annually due to aging demographics and complex diagnostics (more genomic and specialty tests), boosting average revenue per test by ~10% 2022–2025.\u003c\/p\u003e\n\u003cp\u003eCapital intensity remains high—Sonic invested ~US$220m in U.S. lab infrastructure 2024–2025—but the segment now accounts for roughly 28% of group revenue and is the fastest-growing profit center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Pathology and AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeployment of Sonic Healthcare’s proprietary AI diagnostic tools across its ~500-lab global network targets double-digit growth; pilots showed a 20–30% faster turnaround and a 5–10% accuracy lift in 2024 studies, boosting contract wins with large clinics.\u003c\/p\u003e\n\u003cp\u003eMarket leadership in digital pathology drove a 15% rise in high-volume clinical contracts in FY2024, positioning Sonic to set industry standards and expand share in Australia, UK, and US markets.\u003c\/p\u003e\n\u003cp\u003eCapex for scanners, cloud, and AI models reached ~AUD 120m in 2024; ongoing investment is needed but supports a durable cost-per-test advantage and long-term competitive dominance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerman Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSonic Healthcare’s German lab network is a Star: revenue grew ~18% in FY2024 to €420m, driven by consolidation in Europe’s second-largest diagnostics market and share gains versus local labs.\u003c\/p\u003e\n\u003cp\u003eAutomated central hubs raised throughput ~30% since 2022, cutting unit costs; ongoing €45m logistics and automation capex planned for 2025 to sustain growth and aim for Cash Cow margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue €420m, +18%\u003c\/li\u003e\n\u003cli\u003eThroughput +30% since 2022\u003c\/li\u003e\n\u003cli\u003eCapex €45m planned for 2025\u003c\/li\u003e\n\u003cli\u003eTarget: transition to Cash Cow via scale and efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Radiology and Imaging Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced Radiology and Imaging Services is a Star for Sonic Healthcare as demand for MRI and PET-CT rose ~8–10% annually through 2024, outpacing pathology growth; this unit delivered higher margin mixes and contributed materially to group revenue growth in FY2024 (Sonic reported A$2.9bn revenue in FY2024, imaging a growing share).\u003c\/p\u003e\n\u003cp\u003eSonic is investing ~A$120–150m in 2025 across MRI\/PET-CT hardware and teleradiology platforms to support early diagnostic pathways and remote reporting, raising capital intensity versus pathology.\u003c\/p\u003e\n\u003cp\u003eClinical reliance on imaging for oncology and neurology referrals, plus rising private-pay volumes, keeps utilization high and supports continued above-market growth, but heavy capex and reimbursement pressure keep ROI timing critical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth: MRI\/PET-CT ~8–10% p.a. through 2024\u003c\/li\u003e\n\u003cli\u003eCapex: A$120–150m planned 2025\u003c\/li\u003e\n\u003cli\u003eRevenue context: Sonic A$2.9bn FY2024\u003c\/li\u003e\n\u003cli\u003eRisk: high capital intensity and reimbursement pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSonic: Rapid genomic \u0026amp; imaging scale—high margins, heavy capex, path to cash cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Sonic’s precision-medicine, U.S. pathology, German labs, and advanced imaging show high growth, strong margins, and heavy capex—FY2025 genomic revenue AUD420M (+42% YoY), U.S. revenue US$1.1bn, German labs €420M (+18% FY2024), imaging capex A$120–150M planned 2025; aim: scale to Cash Cow via automation, AI, and consolidation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eFY\/2025\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCapex\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics\u003c\/td\u003e\n\u003ctd\u003eAUD420M\u003c\/td\u003e\n\u003ctd\u003e+42% YoY\u003c\/td\u003e\n\u003ctd\u003eAUD85M\u003c\/td\u003e\n\u003ctd\u003eMargins ~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. pathology\u003c\/td\u003e\n\u003ctd\u003eUS$1.1bn\u003c\/td\u003e\n\u003ctd\u003e~6–7% p.a.\u003c\/td\u003e\n\u003ctd\u003eUS$220M (24–25)\u003c\/td\u003e\n\u003ctd\u003e~30 lab adds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGerman labs\u003c\/td\u003e\n\u003ctd\u003e€420M\u003c\/td\u003e\n\u003ctd\u003e+18% FY24\u003c\/td\u003e\n\u003ctd\u003e€45M planned\u003c\/td\u003e\n\u003ctd\u003eThroughput +30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e8–10% p.a.\u003c\/td\u003e\n\u003ctd\u003eA$120–150M planned\u003c\/td\u003e\n\u003ctd\u003eMRI\/PET growth, reimbursement risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix analysis of Sonic Healthcare: quadrant placement, strategic moves for Stars\/Cash Cows\/Question Marks\/Dogs, investment and divestment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Sonic Healthcare units in quadrants for fast strategic decisions and slide-ready export.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAustralian Pathology Core Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Australian pathology market is mature and stable; Sonic Healthcare (ASX:SHL) holds a market-leading share ~30–35% in 2024–25, driving predictable volumes—~A$2.8bn Australian revenue in FY2024—producing steady cash flow with low incremental marketing or capex needs.\u003c\/p\u003e\n\u003cp\u003eHigh regulatory and capital barriers plus Sonic’s trusted brand let the unit fund global M\u0026amp;A (2024 net cash A$350m) and support dividends; operating margins in Australian pathology typically exceed 18–20%, freeing funds for expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Clinical Chemistry and Hematology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoutine clinical chemistry and hematology are Sonic Healthcare’s core cash cows, generating steady revenue—about 45–50% of group test volumes and roughly 30–35% of revenues in FY2024 (company reports)—thanks to high throughput and automation driving margins above 20% in mature markets. \u003c\/p\u003e\n\u003cp\u003eThese standardized tests exploit massive economies of scale: single-platform runs, centralized logistics, and long-term payer contracts yield low incremental costs and predictable, passive cash flow, so management focuses on efficiency gains and margin preservation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished UK and Swiss Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSonic’s mature lab networks in the UK and Switzerland deliver steady EBITDA margins around 18–22% and annual revenues roughly £350–£420m (UK) and CHF 220–260m (Switzerland) in 2024, producing predictable free cash flow. High regulatory barriers—stringent accreditation, data privacy and reimbursement rules—limit new entrants and protect market share. Cash from these operations funds higher-growth APAC investments and repaid corporate net debt, which was about A$1.9bn at FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOccupational Medicine and Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSonic Healthcare’s Occupational Medicine and Screening is a mature niche with a loyal corporate client base, delivering steady revenue—about A$420m of group revenue in FY2024 from community and corporate services, with occupational screening a high-margin contributor. \u003c\/p\u003e\n\u003cp\u003eThese services need minimal capital reinvestment versus high-tech diagnostics, driving strong cash conversion; operating margins often exceed 18% within clinics, supporting free cash flow. \u003c\/p\u003e\n\u003cp\u003eDemand is countercyclical to elective diagnostics, so this segment reliably supports the bottom line through economic cycles and helps fund R\u0026amp;D in specialized labs. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow capex, high cash conversion\u003c\/li\u003e\n\u003cli\u003e~18%+ clinic margins\u003c\/li\u003e\n\u003cli\u003eStable corporate contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term Hospital Laboratory Management Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging internal laboratories for large hospital groups gives Sonic Healthcare Ltd long-term, low-risk revenue: typical contracts run 5–10 years and, per 2024 annual results, pathology services contributed about A$4.1bn of group revenue, with hospital laboratory contracts providing steady double-digit EBITDA margins versus cyclical segments.\u003c\/p\u003e\n\u003cp\u003eThese multi-year agreements need minimal promotional spend once set up, deliver predictable cash flow that funds R\u0026amp;D or acquisitions, and reduced revenue volatility—hospital lab management acted as a liquidity anchor during COVID-19 testing swings in 2020–22.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContract length: 5–10 years\u003c\/li\u003e\n\u003cli\u003e2024 pathology revenue: ~A$4.1bn\u003c\/li\u003e\n\u003cli\u003eMargins: double-digit EBITDA\u003c\/li\u003e\n\u003cli\u003eLow promo spend, high cash stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSonic delivers A$4.1bn pathology revenue in FY24 with stable 18–22% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSonic’s mature pathology and clinic units (Australia, UK, Switzerland, occupational medicine) generated predictable cash flow in FY2024: A$4.1bn pathology revenue, ~A$2.8bn Australia, ~18–22% margins, group net debt ~A$1.9bn, funding dividends, M\u0026amp;A (net cash A$350m in 2024) and R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology revenue\u003c\/td\u003e\n\u003ctd\u003eA$4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralia revenue\u003c\/td\u003e\n\u003ctd\u003eA$2.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK revenue\u003c\/td\u003e\n\u003ctd\u003e£350–420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitzerland revenue\u003c\/td\u003e\n\u003ctd\u003eCHF220–260m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical margins\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup net debt\u003c\/td\u003e\n\u003ctd\u003e~A$1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOccupational revenue\u003c\/td\u003e\n\u003ctd\u003e~A$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eSonic Healthcare BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Sonic Healthcare BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document tailored for portfolio assessment and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748238406009,"sku":"sonichealthcare-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sonichealthcare-bcg-matrix.png?v=1772206324","url":"https:\/\/matrixbcg.com\/products\/sonichealthcare-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}